Market Place
Sourcing Support
Enforcement Report - Week of June 7, 2023
07 Jun 2023 //
FDA
Harrow Closes Acquisition of U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE
23 Jan 2023 //
BUSINESSWIRE
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
20 Dec 2021 //
BUSINESSWIRE
Upsher Smith`s Generic Moxifloxacin Hydrochloride Approved in US
16 Feb 2021 //
FDA
Alembic Pharms`s Generic Moxifloxacin Hydrochloride Receives Approval in US
13 Feb 2019 //
FDA
Sunshine Lake`s Generic Moxifloxacin Hydrochloride Receives Approval in US
02 Oct 2018 //
FDA
Imprimis Pharmaceuticals Receives FDA Warning Letter
17 Jan 2018 //
FDA
Akorn’s Generic Moxifloxacin Hydrochloride Receives Approval In US
13 Nov 2017 //
FDA
Mylan Launches First AP-rated Generic Avelox® Injection
05 Oct 2017 //
PR NEWSWIRE
MSN Lab’s Generic Moxifloxacin Hydrochloride Receives Approval In US
26 Sep 2017 //
FDA
Lupin launches generic conjunctivitis treatment medicine in US
10 Jul 2017 //
ECONOMIC TIMES
Apotex’s Generic Moxifloxacin Hydrochloride Receives Approval In US
04 Jul 2017 //
FDA
Mylan Labs Generic Moxifloxacin Hydrochloride Receives Approval In US
07 May 2017 //
FDA
Novel Labs Inc`s Generic Moxifloxacin Hydrochloride Receives Approval In US
13 Feb 2017 //
FDA
FDA enhances warnings on group of strong antibiotics
26 Jul 2016 //
REUTERS
Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops
03 Feb 2015 //
IMPRIMIS PHARMACEUTICALS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.